Global COVID-19 study opportunities ACM Global Laboratories has been actively involved in supporting COVID-19 vaccine and therapeutic studies. This presents a strong sales opportunity for providing testing services to global clinical trial trials related to COVID-19.

Expansion through acquisitions Through strategic acquisitions like DRUGSCAN, Inc., ACM Global Laboratories has expanded its portfolio and market presence. Leveraging this growth, there is a potential sales avenue to offer a wider range of services to clients looking for comprehensive testing solutions.

Advanced testing services launch The launch of the therapeutic service offering, Smarter Testing for infectious disease, showcases ACM Global Laboratories' commitment to innovation. Sales teams can capitalize on this advanced service to attract clients seeking cutting-edge testing solutions for infectious disease clinical trials.

Robust market positioning In a competitive landscape with key players like bioMérieux and Labcorp, ACM Global Laboratories stands out with its specialized services and global presence. This positions the company as a top choice for organizations looking for a reliable and experienced partner in the biotechnology research sector.

Revenue potential in tech-enhanced testing With a tech stack including Google Ads, Power BI, and Microsoft IIS, ACM Global Laboratories demonstrates a tech-savvy approach to its operations. This tech integration opens sales opportunities to organizations seeking advanced and data-driven testing solutions for their clinical trials and research projects.